Health officials in Europe have announced the next phase of the Myelomeningitis Vaccination Initiative (MIVI) program, a three-year effort to vaccinate tens of thousands of people at an estimated cost of $3.5 billion.
MIVI is being developed as part of the EU’s Vaccine Initiative.
The vaccine will be available in Europe by the end of 2021.
“Europe is now at the peak of the pandemic, with the world facing a pandemic in a few weeks,” EU Commissioner for Health Vytautas Andriukaitis told reporters at a news conference on Thursday.
“It’s an important milestone in the evolution of our EU-wide vaccination initiative, which will be rolled out in 2020, 2020, 2021, and 2030.”
“It will be important for us to ensure the European public has access to a safe and effective vaccine in the event of an emergency,” he added.
The EU has been working with international partners to develop a global vaccine program.
In October, it announced a plan to vaccine all EU citizens by the middle of 2021, but some member states have not been able to meet the target, and there is also concern that vaccines will not be available for some countries.
The European Union is currently working to ensure that all its citizens in the region are vaccinated in a timely manner, but the United States is still waiting on the first dose.
The European Union has already released more than 7 million doses of the vaccine and is aiming to distribute more by the start of 2019.
EU health officials say the vaccine will protect people from more than 100,000 Myeloblastomas, a type of coronavirus that is more common in Europe.
“There is a very high level of concern among people in Europe and the world about the spread of coronapas,” Andriau told reporters.
“So the European vaccine initiative is the first step towards providing a vaccine to all European citizens.
It is an important step in our vaccination effort and it’s also an important signal to the world.”
The vaccine is being released in the hope that it will protect against more severe forms of the disease, which is also common in Asia and Africa.
The WHO has said that coronaviruses are the most deadly type of infectious disease.
The World Health Organization says about 5.6 million people in the EU and about 10.8 million people worldwide are at risk of developing coronaviral disease.
The vaccine was first approved in Europe, but was pulled after it was discovered that some of the patients it was designed to protect were infected with other, potentially more deadly diseases.
The first clinical trial of the MIVi vaccine was not completed until 2021.
The new vaccine will not make it into clinical trials in the United Kingdom, but will be in trials in Spain, Portugal, Germany, Italy, and France.
A total of 2.2 million doses will be given out to EU residents each year until 2022, according to the WHO.
The majority of doses are given to adults, and will be distributed to people who have a medical need for the vaccine.
The remaining doses will mainly be given to people living in the European Union.